As the global AI industry enters an explosive growth phase, continuous upgrades in compute infrastructure are revolutionizing the biomedical sector. Chai Discovery stands out in this wave by deeply integrating advanced large language models with molecular science, pioneering a new drug discovery paradigm. The company aims to build a "computer-aided design (CAD) suite for molecules," using cutting-edge AI algorithms to precisely predict biomolecular interactions. This enables the de novo design of novel therapeutic molecules—rather than simply tinkering with existing structures—offering potential solutions to previously "undruggable" targets while dramatically boosting R&D efficiency.\n\n\nThe Series B round was co-led by General Catalyst and Oak HC/FT, with continued participation from Menlo Ventures, OpenAI, Dimension, Thrive Capital, and new strategic investors Glade Brook and Emerson Collective. This premium investor lineup underscores strong capital market confidence in the AI-bio convergence. Notably, since its founding in 2024, Chai Discovery has rapidly raised over $225 million in total funding, reflecting exceptional capital-attraction and time-to-market velocity.\n\n\nThe company's flagship Chai2 model represents the cutting edge of AI drug design, achieving breakthroughs in creating customized antibodies from scratch. Compared to traditional methods, the model significantly improves success rates, especially for challenging "undruggable" targets.
Co-founder and CEO Josh Meier, who previously conducted frontier AI research at OpenAI and led machine learning engineering at Meta, noted: "Our latest model can design molecules with the physicochemical and biological properties required for real drugs, addressing high-difficulty targets that have long remained out of reach." Meier's deep AI expertise lays a solid foundation for Chai's technological trajectory, enabling full integration of the latest AI advances.\n\n\nChai Discovery's rapid ascent is no accident, but a natural outcome of the broader AI drug development trend. Traditional drug R&D faces long cycles, high costs, and high failure rates; AI promises to transform this from a "trial-and-error experiment" into "precision design." As large AI models continue evolving, the fusion of biomedicine and AI is becoming an irreversible industry trend. Chai's bet on the "foundation model + molecular science" paradigm has not only attracted global capital but also drawn top-tier talent into this cross-disciplinary field, creating a virtuous cycle of innovation.\n\n\nWith dual propulsion from the OpenAI ecosystem and top venture capital, Chai Discovery is quickly moving from theoretical validation to practical drug discovery. In just over a year, the company has bridged concept to product, highlighting AI's application potential in biomedicine. As the Chai2 model enters real-world use, this startup is not only seeing its valuation soar but is also positioning itself as a potential definer of the AI-native drug development era—rewriting the rules of new drug R&D with algorithms and bringing transformative change to human health, while offering a successful model for vertical AI applications.